for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

245.58USD

Change

-2.30(-0.93%)

Volume

784,967

Today's Range

243.21

 - 

253.08

52 Week Range

143.13

 - 

275.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
247.88
Open
252.13
Volume
784,967
3M AVG Volume
60.51
Today's High
253.08
Today's Low
243.21
52 Week High
275.60
52 Week Low
143.13
Shares Out (MIL)
956.59
Market Cap (MIL)
234,920.00
Forward P/E
30.76
Dividend (Yield %)
1.38

Next Event

Eli Lilly and Co Investment Community Meeting

Latest Developments

More

FDA Expands Authorization Of Two Monoclonal Antibodies For Treatment Of Covid-19 To Younger Pediatric Patients, Including Newborns

Innovent Biologics Says PD-1 Inhibitor Tyvyt Successfully Included In Updated NDRL

Adage Capital Partners Raises Stake in Tesla, Merck, Takes In Moderna, Novavax

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

INDIANAPOLIS, IN

46285-0001

United States

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Anat Ashkenazi

Chief Financial Officer, Senior Vice President

Aarti S. Shah

Senior Vice President, Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer, President, Lilly Research Laboratories

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer

Key Stats

2.00 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

24.6K

2019

22.3K

2020

24.5K

2021(E)

27.5K
EPS (USD)

2018

5.550

2019

6.040

2020

7.930

2021(E)

7.984
Price To Earnings (TTM)
37.51
Price To Sales (TTM)
8.46
Price To Book (MRQ)
30.28
Price To Cash Flow (TTM)
31.57
Total Debt To Equity (MRQ)
220.26
LT Debt To Equity (MRQ)
200.11
Return on Investment (TTM)
18.07
Return on Equity (TTM)
12.96

Latest News

Latest News

Factbox-Latest on the worldwide spread of the coronavirus

Europe crossed 75 million coronavirus cases according to a Reuters tally, as the region braces for the new Omicron variant at a time when hospitals in some countries are already strained by the current surge.

FDA clears use of Lilly's COVID-19 antibody therapy for kids

The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness.

Factbox-Front runners in development of antibody drugs against COVID-19

AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies.

U.S. buys more doses of Lilly's COVID-19 treatment for $1.29 billion

Eli Lilly and Co said on Tuesday that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion.

Lilly kicks off application for Alzheimer's drug U.S. approval

Eli Lilly said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and expects a regulatory decision by the second half of 2022, potentially setting it up against rival Biogen's recently approved Aduhelm.

Govt to control distribution of GSK/Vir COVID-19 antibody in U.S. - FDA

The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline and Vir Biotechnology's antibody treatment for COVID-19 would be controlled by the government.

EU signs joint procurement deal for Eli Lilly COVID-19 treatment

The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday.

Lilly to supply up to 220,000 COVID-19 antibody combo doses to European countries

Eli Lilly on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease.

Eli Lilly to supply up to 220,000 doses of its COVID-19 antibody combo to EU

Eli Lilly on Tuesday announced a pact with the European Commission (EC) to supply up to 220,000 doses of its COVID-19 dual antibody cocktail for patients aged 12 years and older who are at a high risk of progressing to severe disease. (Reporting by Manojna Maddipatla in...

U.S. buys additional doses of Eli Lilly's COVID-19 therapy

Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, etesevimab.

Lawsuit claims Eli Lilly favors millennials for sales jobs

Eli Lilly and Co was accused in a proposed class action filed on Wednesday of systematically refusing to interview and hire older workers for sales representative jobs, opting instead to target millennials and recent college graduates.

U.S. resumes supply of Lilly's COVID-19 antibody combo to some states

U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies. The Department of Health...

Regeneron sees uptick in COVID-19 therapy use as cases rise

Regeneron Pharmaceuticals Inc on Thursday blew past analysts' estimates for second-quarter profit and revenue and said it has seen a recent uptick in the use of its COVID-19 therapy by patients in the United States.

'Tug of war' as investors digest mixed market messages

U.S. stocks rose, 10-year Treasuries were flat and oil prices fell on Tuesday as markets weighed mixed signals from corporate earnings and economic growth data.

Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation

Eli Lilly and Co and partner Incyte Corp said on Tuesday additional results from a late-stage study showed their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.

EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies

The European Commission on Tuesday picked four antibody treatments and a repurposed rheumatoid arthritis drug by Eli Lilly for an initial portfolio of preferred drugs to treat COVID-19.

U.S. pauses distribution of Lilly's COVID-19 antibody combination therapy

U.S. health officials on Friday paused the distribution of Eli Lilly's COVID-19 antibody cocktail therapy as it failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.

Lilly to seek accelerated FDA approval for Alzheimer's drug this year

Eli Lilly and Co said it will seek accelerated approval from the U.S. health regulator this year for its Alzheimer's candidate, weeks after a rival drug from Biogen Inc won the agency's endorsement using the same regulatory pathway.

U.S. authorizes Regeneron's COVID-19 antibody therapy for injection

The U.S. health regulator authorized a lower dose of Regeneron Pharmaceutical's COVID-19 antibody cocktail that can be given by injection, a move that could ease logistical challenges stemming from administering a higher dose intravenously.

Eli Lilly gets Indian emergency use nod for COVID-19 antibody drug combination

Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate COVID-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up